1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
YUNGJIN PHARM. CO. LTD

YUNGJIN PHARM. CO. LTD

KKRX:003520
986.00
KRW
-9.00
(-0.90%)
-34.21EPS
217.46BMarket Cap
YUNGJIN PHARM. CO. LTD
KRX:003520
(Korea Stock Exchange)

Recent

price

986.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
806.13
631.15
767.4
880.33
921.63
954.98
1,103.05
1,044.1
1,008.29
1,227.54
1,139.81
1,066.46
1,193.28
1,272.84
1,378.08
1,390.19
1,383.35
Revenue per Share
-16
14.53
10
66
5
19
24
10
-33
28
-0.73
-63
-120
-21
6.74
-1.24
-34.21
Basic EPS, GAAP
21.65
-32.27
-5.41
-4.34
-29.17
-36.09
-10.09
-41.96
-18.57
-5.99
44.8
-16.06
-135.57
-110.87
0.73
-1.28
-42.74
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
504.64
506.02
512.72
576.77
567.44
565.39
597.73
654.21
610.23
632.89
625.68
573.48
491.38
490.08
491.02
500.07
471.08
Book Value per Share
485.95
486.13
490.25
566.25
557.04
552.01
584.99
611.61
597.44
620.79
617.12
565.6
476.73
477.42
481.81
490.33
458.36
Tangible Book Value per Share
144
178
179
178
182
178
175
187
185
180
183
184
183
185
183
183
183
Basic Weighted Avg Shares
116,317
112,105
137,688
156,623
167,569
170,203
193,134
195,009
186,409
220,516
208,464
196,067
218,381
234,902
252,040
254,256
253,003
Sales/Revenue/Turnover
1.78
3.78
2.37
4.42
4.16
2.97
2.82
1.55
-1.17
4.53
0.18
-7.08
-3.37
1.33
3.46
1.9
-1.16
Operating Margin (%)
3,653
3,971
4,627
4,895
4,914
5,863
5,830
6,602
6,642
7,646
7,780
7,378
7,780
8,693
8,715
8,785
9,082
Depreciation Expense
-2,309
2,581
1,794
11,742
909
3,386
4,202
1,868
-6,101
5,030
-133
-11,582
-21,961
-3,876
1,233
-228
-6,256
Net Income, GAAP
- -
19.18
30.94
- -
85.93
25.59
21.07
33.02
- -
46.5
155.18
- -
- -
- -
57.3
- -
- -
Effective Tax Rate (%)
-1.98
2.3
1.3
7.5
0.54
1.99
2.18
0.96
-3.27
2.28
-0.06
-5.91
-10.06
-1.65
0.49
-0.09
-2.47
Profit Margin (%)
32,241
32,224
36,341
44,159
39,449
51,585
79,812
76,550
71,582
71,543
68,535
41,359
52,563
51,509
9,185
47,124
36,029
Working Capital
1,540
9,036
9,625
3,096
5,730
13,777
12,458
10,292
8,125
6,122
3,949
2,153
27,586
40,867
4,631
49,193
38,299
LT Debt
89,634
89,880
91,068
102,445
100,789
100,424
106,168
119,650
111,606
115,751
114,432
104,885
89,870
89,632
89,803
91,459
86,157
Total Equity
- -
2.88
1.92
- -
0.81
3.05
3.38
1.51
- -
4.16
-0.17
- -
- -
- -
2.39
- -
- -
Return on Invested Capital (%)
- -
2.96
2.36
- -
0.83
3.27
3.77
1.63
- -
4.06
-0.22
- -
- -
- -
2.24
- -
- -
Return on Capital (%)
-3.07
2.88
1.98
12.14
0.89
3.37
4.07
1.65
-5.28
4.42
-0.12
-10.56
-22.55
-4.32
1.37
-0.25
-7.06
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
44,802
35,815
38,943
LT Borrowings
48,723
49,091
38,178
LT Finance Leases
470
241
121
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
183
183
183
Market Capitalization
365,785
313,843
217,459

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
145,631
117,761
112,266
Cash, Cash Equivalents & STI
28,427
6,265
3,587
Accounts Receivable, Net
48,810
45,865
42,614
Inventories
66,179
63,130
63,456
Total Current Liabilities
98,508
70,858
76,237
Payables & Accruals
- -
- -
- -
ST Debt
44,802
35,815
38,943
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.66%
-4.18%
1.84%
Free Cash Flow
-50.44%
42.3%
-274.73%
Net Income, GAAP
761.44%
1,671.53%
-118.47%
Sales/Revenue/Turnover
4.4%
4.24%
0.88%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
64,946
62,202
62,040
62,853
252,040
2025
64,074
62,516
60,850
66,816
254,256
2026
63,759
61,578
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
22
-8
-2
-5.29
6.74
2025
5
2
-6.38
-2.05
-1.24
2026
-12.48
-13.29
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Yungjin Pharm. Co., Ltd. functions as a prominent pharmaceutical entity, deeply rooted in South Korea's healthcare sector. The company delivers a diverse portfolio encompassing advanced cephalosporin antibiotics, treatments for psychiatric and cardiovascular conditions, and a variety of nutritional products. Established in 1952, this firm, known for its extensive research and development endeavors, maintains its corporate headquarters in Seoul, South Korea. Yungjin Pharm. Co., Ltd. operates as an integral part of the KT&G Corporation group.